Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

EvidenceVariable: PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)

Computable Name:

version: 14; Last updated: 2026-09-02 17:15:21+0000

Profile: VariableDefinition

ArtifactPublicationStatus: Active

url: https://fevir.net/resources/EvidenceVariable/267231

identifier: FEvIR Object Identifier/267231, FEvIR Linking Identifier/NCT03421379-secondaryOutcome-4

name: PK_Change_From_Baseline_in_Tmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_IM_NCT03421379

title: PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)

citeAs:

PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267231. Revised 2026-09-02. Available at: https://fevir.net/resources/EvidenceVariable/267231. Computable resource at: https://fevir.net/resources/EvidenceVariable/267231#json.

status: Active

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

PK assessment measured the change from baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM.

copyright:

Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).

Definitions

-Concept
*PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM PK assessment measured the change from baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM.

handling: Evidence variable handling not specified

Timings

-Text
*Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration